Why the study?
Does lacosamide co-medication induce ventricular tachycardia in epilepsy patients with cardiac risk factors?
Does lacosamide co-medication induce ventricular tachycardia in epilepsy patients with cardiac risk factors?
Lacosamide use in epilepsy patients with cardiac risk factors may be associated with severe ventricular arrhythmias and conduction defects.
Lacosamide may be associated with ventricular arrhythmias in epilepsy patients with cardiac risk factors; single case leaves need for prospective confirmation open.
We report a case of sustained ventricular tachycardia following the initiation of lacosamide as adjunctive epilepsy treatment. A 49-year-old male with intractable frontal lobe seizures experienced severe ventricular tachycardia following the addition of 400 mg lacosamide to his existing regimen of carbamazepine, lamotrigine, clonazepam, and valproate. The tachycardia occurred during a cardiac stress test; stress tests prior to initiation of lacosamide were normal. Conduction defects, including QRS prolongation, persisted during hospitalization until lacosamide was discontinued. The patient had no prior history of cardiac arrhythmia but did possess cardiac risk factors, including hypertension, hypercholesterolemia, and low heart rate variability. This case represents one part of a growing body of literature suggesting a link between arrhythmia and use of lacosamide, which enhances slow inactivation of sodium channels in both the brain and the heart. We believe further study may be necessary to assess the safety of lacosamide in epilepsy patients with cardiac risk factors.
No takes yet. Share an insight, caveat, or question.
DeGiorgio et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: